Literature DB >> 20157775

TGFB1 T29C polymorphism and breast cancer risk: a meta-analysis based on 10,417 cases and 11,455 controls.

Dongying Gu1, Luhong Zhuang, Huaying Huang, Ping Cao, Danling Wang, Jinhai Tang, Jinfei Chen.   

Abstract

Breast cancer is the most prevalent cancer worldwide. Many published articles have evaluated the association between the transforming growth factor beta 1 (TGFB1) T29C polymorphism and breast cancer risk. However, the results remain inconclusive. In order to derive a more precise estimation of the association, a meta-analysis was performed in this study. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association. A total of 12 studies including 10,417 breast cancer cases and 11,455 controls were identified. Overall, no significant associations between the TGFB1 T29C polymorphism and breast cancer risk were found for CC versus TT (OR = 1.00, 95% CI = 0.92-1.09), TC versus TT (OR = 0.98, 95% CI = 0.93-1.05), CC/TC versus TT (OR = 0.99, 95% CI = 0.93-1.05), and CC versus TC/TT (OR = 1.00, 95% CI = 0.93-1.08). In the subgroup analysis by ethnicity, source of controls, and menopausal status, there was still no significant association detected in all genetic models. In conclusion, the present meta-analysis suggests that the TGFB1 T29C polymorphism is not a low-penetrant risk factor for developing breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20157775     DOI: 10.1007/s10549-010-0766-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Pathway analyses identify TGFBR2 as potential breast cancer susceptibility gene: results from a consortium study among Asians.

Authors:  Xiangyu Ma; Alicia Beeghly-Fadiel; Wei Lu; Jiajun Shi; Yong-Bing Xiang; Qiuyin Cai; Hongbing Shen; Chen-Yang Shen; Zefang Ren; Keitaro Matsuo; Ui Soon Khoo; Motoki Iwasaki; Jirong Long; Ben Zhang; Bu-Tian Ji; Ying Zheng; Wenjing Wang; Zhibin Hu; Yao Liu; Pei-Ei Wu; Ya-Lan Shieh; Shenming Wang; Xiaoming Xie; Hidemi Ito; Yoshio Kasuga; Kelvin Y K Chan; Hiroji Iwata; Shoichiro Tsugane; Yu-Tang Gao; Xiao Ou Shu; Harold L Moses; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-04-26       Impact factor: 4.254

2.  TGF-β1-509C/T polymorphism and the risk of ESCC in a Chinese Han population.

Authors:  Hong-Jian Liu; Qing-Guang Zhang; Yu-Bo Wang; Hai-Tao Xu; Jing-Jing Zhang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Evaluation of rs1982073 polymorphism of transforming growth factor-β1 in glioblastoma.

Authors:  Yasaman Sadeghi; Pouya Tabatabaei Irani; Laleh Rafiee; Mohamadhasan Tajadini; Alireza Amouheidari; Shaghayegh Haghjooy Javanmard
Journal:  J Res Med Sci       Date:  2019-05-22       Impact factor: 1.852

4.  Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.

Authors:  Zoi Lanara; Efstathia Giannopoulou; Marta Fullen; Evangelos Kostantinopoulos; Jean-Christophe Nebel; Haralabos P Kalofonos; George P Patrinos; Cristiana Pavlidis
Journal:  Hum Genomics       Date:  2013-06-05       Impact factor: 4.639

5.  Strong impact of TGF-β1 gene polymorphisms on breast cancer risk in Indian women: a case-control and population-based study.

Authors:  Singh Pooja; Amirtharaj Francis; Singh Rajender; Rakesh Tamang; Raja Rajkumar; Karan Singh Saini; Kaling Megu; Madhu Mati Goel; Daminani Surekha; Digumarthi Raghunatha Rao; Lakshmi Rao; Lingadakai Ramachandra; Sandeep Kumar; Surender Kumar; Satti Vishnupriya; Kapaettu Satyamoorthy; Mahendra Pal Singh Negi; Kumarasamy Thangaraj; Rituraj Konwar
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.